Stand Up To Cancer’s mission is to raise awareness and fund research to detect and treat cancers with the aspiration to cure all patients.
Focus Areas
Early detectionCancer interceptionImmunotherapy and cancer vaccinesClinical trialsAI and computational approachesPancreatic cancerBreast cancerLung cancerPediatric cancerColon and rectal cancerProstate cancerLeukemiaMelanomaOvarian cancerMyeloma
About Stand Up to Cancer
Stand Up to Cancer’s recent grantmaking is defined by two large general-program awards to the Entertainment Industry Foundation, one in 2024 for $38,933,153 and another in 2025 for $34,661,350. Those grants sit within a mission centered on raising awareness and funding research to detect and treat cancers, with the stated aspiration to cure all patients. The foundation’s focus areas point to a broad research agenda that includes early detection, cancer interception, immunotherapy and cancer vaccines, and clinical trials, alongside disease-specific work in pancreatic, breast, lung, pediatric, colon and rectal, prostate, leukemia, melanoma, ovarian, myeloma, brain tumors, and endometrial cancer.
The pattern suggests a research funder oriented toward accelerating clinical progress rather than making many small awards. Its beneficiary list includes people living with cancer, underserved and minority communities affected by cancer, and clinical researchers and trial investigators. The support also aligns with a collaborative, consortium-driven approach and with funding that aims to speed therapy development and deployment. In the recent grants on file, the foundation’s giving is tightly concentrated and channels major resources through a repeated partner in Los Angeles.
What Stand Up to Cancer Funds
In early detection and cancer interception, Stand Up to Cancer names both areas as core parts of its funding agenda, linking them to its mission to detect and treat cancers. Its program areas also include immunotherapy and cancer vaccines, showing support for treatment development as well as prevention-oriented research.
Disease-specific funding covers several cancer types. The foundation lists pancreatic cancer, breast cancer, lung cancer, pediatric cancer, colon and rectal cancer, prostate cancer, leukemia, melanoma, ovarian cancer, myeloma, brain tumors, and endometrial cancer among its focus areas. That breadth suggests a portfolio built around multiple tumor types rather than a single disease. The taxonomy also includes AI and computational approaches, clinical trials support, and therapy development/rapid deployment, which points to research translation as a central theme.
How Stand Up to Cancer Gives
The only grant-size figures on file are $38,933,153 and $34,661,350, which place the typical grant size at $38,933,153 across the observed record. The recent grants list shows repeated support to the same recipient in consecutive years, indicating an ongoing relationship rather than a one-off award pattern. Stand Up to Cancer is classified as a regular funder, does not fund individuals, and is not a program-related-investment maker. No application process is provided in the available data.
Financial Snapshot
Annual Giving
$69.3M
Total Assets
$0
Total Revenue
$34.7M
Total Expenses
$34.7M
Typical Grant Size
Most grants fall between $38.9M and $38.9M, with a median of $38.9M.
25th Percentile
$38.9M
Median
$38.9M
75th Percentile
$38.9M
Geographic Reach
Local1 state funded
Funding intensity
LowHigh
Headquarters
Leadership
NICOLE SEXTON
Accepts unsolicited proposals
Deep Analysis
Unlock Deep Analysis
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
people living with cancerunderserved/minority communities affected by cancerclinical researchers and trial investigators
Funding Style
accelerated/translational fundingclinical trial supportcatalytic/grantmaking to speed therapiescollaborative/consortium-driven funding
Topics
cancer researchtranslational researchclinical trials supporttherapy development/rapid deploymentcancer health equity
Where Stand Up to Cancer Makes Grants
Stand Up to Cancer’s grantmaking is local and entirely concentrated in California, which accounts for 100% of grants in the dataset. The recent awards both went to Los Angeles, CA. At the country level, all recorded grants stayed in the United States. The location pattern is narrow rather than dispersed, with giving landing in the foundation’s own state and city through its main recipient.
Frequently Asked Questions About Stand Up to Cancer
What kinds of cancer research does Stand Up to Cancer support?
Its stated focus areas include early detection, cancer interception, immunotherapy and cancer vaccines, clinical trials, AI and computational approaches, and multiple disease areas such as pancreatic, breast, lung, pediatric, colon and rectal, prostate, leukemia, melanoma, ovarian, myeloma, brain tumors, and endometrial cancer.
Who receives grants from Stand Up to Cancer?
The beneficiary types listed are people living with cancer, underserved and minority communities affected by cancer, and clinical researchers and trial investigators. The recent grants on file also show support going to a Los Angeles-based recipient in the general-program category.
Does Stand Up to Cancer make individual grants?
No. The foundation is marked as funds individuals: false, so its giving is directed to organizations rather than individuals.
What is the typical grant size at Stand Up to Cancer?
The typical grant size is $38,933,153, with p25, median, and p75 all at the same figure. The recent grants list shows one award at that amount in 2024 and another at $34,661,350 in 2025.
Where does Stand Up to Cancer give?
Its geographic scope is local, and 100% of grants in the dataset went to recipients in California. The recorded recipients were in Los Angeles, CA, and all grants were in the United States.
Who can apply: The opportunity is intended for teams conducting highly innovative translational research on DMG, including DIPG, with potential for significant improvements in long-term survival and quality of life for children and young adults. Specific institutional eligibility details are provided through ProposalCentral.
Deadline: Application deadline: September 30, 2026.
Stand Up To Cancer–PNOC and PNOC Foundation Diffuse Midline Glioma Discoveries Challenge Grant Program
Pediatric neuro-oncologyDiffuse midline gliomaDiffuse intrinsic pontine glioma+2 more
Who can apply: Specific eligibility requirements are provided in the RFA. The opportunity is intended for highly innovative translational research teams working on DMG, including DIPG.
Cancer researchEarly detection and cancer interceptionCancer treatment and clinical trials+4 more
Who can apply: Applicants must submit novel, collaborative, high-impact cancer research proposals responding to a published SU2C Request for Applications. SU2C emphasizes defined milestones and deliverables, collaboration, team science, health-equity goals, and inclusion of historically underrepresented racial, ethnic, sovereign-nation, and underserved populations where relevant. Specific eligibility varies by RFA.
Deadline: No traditional grant cycle; RFAs open when funds are available. New opportunities are posted on the SU2C Grant Opportunities page.
Cancer researchEarly detection and cancer interceptionCancer treatment+10 more
Who can apply: Applicants must submit novel, collaborative, high-impact cancer research proposals responsive to an announced Stand Up To Cancer Request for Applications. Proposals should address critical patient-care problems, have defined milestones and deliverables, and incorporate health-equity considerations where relevant. Specific eligibility varies by RFA.
Deadline: No traditional grant cycle; RFAs are opened as funds become available. Current open applications are posted on the Grant Opportunities page.
Deadlines and eligibility are summarized from public sources and may change — always confirm the details on the funder's official application page before applying.
